



Republic of the Philippines
Department of Health
CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

COBAC RESOLUTION NO. 2018-377

20 June 2018

**RECOMMENDING APPROVAL OF THE AWARD OF CONTRACT
FOR THE PROCUREMENT OF PREDNISONE, 10MG
IB NO. 2018-144**

WHEREAS, Open Competitive Bidding for the Procurement of Prednisone, 10mg was conducted in accordance with Republic Act (RA) 9184 and its 2016 Implementing Rules and Regulations (IRR) through the General Appropriations Act of 2018 with a Total Approved Budget for the Contract (ABC) of Five Million Philippine Pesos (PhP5,000,000.00):

Item No.	Particular	Quantity	Unit	Total ABC (PhP)
1	Prednisone, 10mg	2,000,000	Tablet	5,000,000.00

WHEREAS, on 12 February 2018, a PR was received from Disease Prevention and Control Bureau – Leprosy Program (DPCB-LP);

WHEREAS, on 20 February 2018, Pre-procurement Conference was conducted at 10:00 AM at COBAC Conference Room, Department of Health (DOH) to discuss the details of the procurement at hand;

WHEREAS, the Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-081 dated 23 February 2018;

WHEREAS, on 26 February 2018, the Invitation to Bid (IB) was posted in the PhilGEPS website and in other conspicuous places within the premises of the DOH. The advertisement of the IB in newspaper of general nationwide circulation pursuant to Section 31.2.1(c) of the 2016 IRR of RA 9184 shall not be required for contracts to be bid with an ABC of PhP10M and below for the procurement of goods;

WHEREAS, a Bid Bulletin No. 1, dated 05 March 2018 was issued to announce the new schedule of Pre-bidding Conference previously slated on 06 March 2018;

WHEREAS, on 07 March 2018, the Pre-bidding Conference took place as re-scheduled at 9:00 AM at the COBAC Conference Room, DOH with three (3) prospective bidders participating, namely:

1. Metro Drug, Inc. (MDI);
2. Glorso Medica (GM); and,

3. Westfield Pharmaceuticals, Inc. (WPI).

WHEREAS, on 20 March 2018, the Submission and Opening of Bids took place as scheduled at 9:00 A.M. at the COBAC Conference Room, DOH. Four (4) prospective bidders bought the bidding documents and subsequently submitted their respective bids, namely:

1. MDI JV with Interpharma Holdings and Management Corporation (IHMC);
2. Sel-J Pharma Corporation (SJPC);
3. GM; and,
4. Lunarmed Pharma Trading (LPT).

WHEREAS, the first envelopes, containing the Eligibility and Technical Documents were individually opened and the presence, completeness and correctness of all the documents were verified by the COBAC-A in the presence of the bidders' representatives. Upon examination, MDI JV with IHMC, SJPC, GM and LPT were declared "ELIGIBLE";

WHEREAS, the second envelopes containing the Financial Proposals were individually opened and the presence, completeness and correctness of the Financial Documents were verified by the COBAC-A. Upon examination, the four (4) "ELIGIBLE" bidders were also rated "PASSED" and their respective proposals were read out publicly and posted in the Abstract of Bids, to wit:

Name of Company					MDI JV with IHMC	SJPC	GM	LPT
Bid Security					LC	BSD	BSD	BSD
Amount					100,000.00	N/A	N/A	N/A
Validity					18-Jul-2018	N/A	N/A	N/A
REMARKS					ELIGIBLE / PASSED	ELIGIBLE / PASSED	ELIGIBLE / PASSED	ELIGIBLE / PASSED
Item No.	Item Description	Qty.	Unit	TOTAL ABC	BID PRICE AS READ (PhP)			
1	Prednisone, 10mg	2,000,000	Tube	5,000,000.00	2,500,000.00	2,980,000.00	3,960,000.00	1,696,000.00

WHEREAS, LPT was declared Lowest Bidder (LB), subject to further arithmetical review and corrections of the financial bid, to determine the bonafide Lowest Calculated Bid (LCB);

WHEREAS, the bid for the item listed below were found to be substantially complying:

Item No. 1: 2,000,000 tablets of Prednisone, 10mg

Bidder No.	Company Name	ABC (PhP)	Bid as Read Amount (PhP)	% Variance from ABC
4	LPT	5,000,000.00	1,696,000.00	66.08%
1	MDI JV with IHNC		2,500,000.00	50.00%
2	SJPC		2,980,000.00	40.40%
3	GM		3,690,000.00	26.20%

WHEREAS, on 21 March 2018, the detailed evaluation of the submitted proposal on the legal, technical and financial aspects of the documents of the LCB was undertaken by the designated TWG;

WHEREAS, on 24 March 2018, the legal and financial TWG members upon evaluation found LPT as “complying” as to legal and financial requirements and submitted their evaluation;

WHEREAS, on 02 April 2018, one of the technical TWG members submitted its evaluation and found that the validity and effectivity dates of submitted Distributor Agreement was not specified;

WHEREAS, an amendment on the composition of Technical Working Group (TWG) was created through the issuance of Department Personnel Order (DPO) COBAC No. 2018-081-A dated 28 March 2018;

WHEREAS, on 13 April 2018, one of the technical TWG members submitted its evaluation and found LPT “complying”;

WHEREAS, on 18 April 2018, the TWG report was presented to the COBAC-A during its 16th Regular Meeting and upon further review and deliberation, the Committee found that the validity and effectivity dates was indicated in the submitted Distributor Agreement and subsequently decided to endorse the said document to the TWG for further review and evaluation;

WHEREAS, on the same date, the cited document was endorsed to the TWG for further review and evaluation;

WHEREAS, on 19 April 2018, the technical TWG submitted its evaluation and found LPT “complying”;

WHEREAS, on 24 April 2018, the TWG report was presented to the COBAC-A during its 17th Regular Meeting and upon further review and deliberation, the Committee decided to proceed with the post-qualification evaluation upon receipt of the additional documentary requirements;

WHEREAS, on the same date, a notification was issued to LPT requesting for the submission of the post-qualification requirements;

WHEREAS, on 30 April 2018, LPT submitted its post-qualification requirements which was considered within the prescribed timeline wherein if the deadline for an activity falls on a non-working day (i.e. Saturday and Sunday), then the submission will be the next working day pursuant to Section 38.2 of 2016 IRR of RA 9184;

WHEREAS, on the same date, the post-qualification requirements were submitted by LPT and was subsequently forwarded to the TWG for evaluation;

WHEREAS, on 11 May 2018, the TWG, upon evaluation of the submitted post-qualification requirements, found that the distributor was not indicated in the imprint of the submitted sample packaging;

WHEREAS, on 15 May 2018, the TWG post-qualification report was presented to the COBAC-A during its 19th Regular Meeting and upon further review and deliberation, the Committee decided to issue a letter requesting for clarification relative to the above cited finding;

WHEREAS, on 17 May 2018, a letter was issued to LPT requesting for clarification relative to the above cited finding;

WHEREAS, on 23 May 2018, LPT submitted its response and another sample packaging indicating the manufacturer and distributor of the product;

WHEREAS, on 30 May 2018, the response of LPT was presented to the COBAC-A during its 19th Regular Meeting and upon further review and deliberation, the Committee decided to endorse the cited document to the TWG for further review and evaluation;

WHEREAS, 04 June 2018, the cited document was forwarded to the TWG for further review and deliberation;

WHEREAS, 10 June 2018, the TWG, upon evaluation of the cited document, found LPT “responsive” and subsequently submitted its evaluation;

WHEREAS, 13 June 2018, the TWG report was presented to the COBAC-A during its 23rd Regular Meeting and upon further review and deliberation, the Committee concurred with the TWG and declared LPT “post-qualified”;

WHEREAS, on 16 June 2018, the TWG submitted the Bid Evaluation and Post-qualification Evaluation Reports citing LPT “responsive” on the submitted documents;

WHEREAS, the COBAC-A reviewed and deliberated the TWG report, as well as the documents and response submitted by the LCB and the following are the salient points of discussion:

Item No.	Description	Name of Bidder	ABC (PhP)	Bid Price (PhP)	TWG		COBAC-A	
					Finding	Recommendation	Finding	Recommendation
1	Prednisone, 10mg	LPT	5,000,000.00	1,696,000.00	The LCB passed the evaluation and found to have complied with the legal, technical and financial requirements.	Complying	<ul style="list-style-type: none">• COBAC-A conforms with the recommendation of the TWG.• LPT is determined to be responsive and post-qualified and recommended for the award of contract.	Lowest Calculated and Responsive Bid (LCRB)

WHEREAS, at the time of signing of this Resolution, there is no pending incident, no pending Request for Reconsideration, no pending protest and the COBAC-A followed the requirements set forth in RA 9184;

NOW THEREFORE, on the basis of the above, the herein members of the COBAC-A **HEREBY RESOLVES** to recommend the award of contract to **Lunarmed Pharma Trading** with a Total Contract Price of **One Million Six Hundred Ninety Six Thousand Philippine Pesos (PhP1,696,000.00)** inclusive of taxes for the item listed below:

Item No.	Particular	Qty.	Unit	Total Bid Price (PhP)
1	Prednisone, 10mg	2,000,000	Tablet	1,696,000.00

Signed this AUG 14 2018 day of _____ 2018 at the Department of Health, San Lazaro Compound, Sta. Cruz, Manila.


CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – A


LEONITA P. GORGOLON, MHA, MCHM, CEO VI
Regular Member


FERCHITO L. AVELINO, MD, PHSAE
Regular Member


MAR WYNN C. BELLO, MD, MPA
Regular Member


KENNETH G. RONQUILLO, MD, MPH, CESO III
Vice-Chairperson


NESTOR F. SANTIAGO, JR., MD, MPH, MHSA, CESO III
Assistant Secretary of Health
Chairperson

By Authority of the Secretary of Health:


MYRNA C. CABOTAJE, MD, MPH, CESO III
Director IV
Disease Prevention and Control Bureau
AUG 29 2018